Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor
Author:
Affiliation:
1. Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA
2. Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA
Publisher
Informa UK Limited
Subject
Cancer Research,Oncology,Hematology
Link
https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1797008
Reference24 articles.
1. Targeting FLT3 mutations in AML: review of current knowledge and evidence
2. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm
3. Gilteritinib: potent targeting of FLT3 mutations in AML
4. Myeloproliferative neoplasms with concurrent BCR–ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group
5. Tyrosine kinase inhibitor therapy for acute myeloid leukemia with late-appearing Philadelphia chromosome
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance;Cancers;2023-03-06
2. Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after enasidenib treatment;Leukemia & Lymphoma;2021-06-21
3. Acquired BCR-ABL1 fusion and IDH1 clonal evolution following BCL2 inhibitor treatment in refractory acute myeloid leukemia;Leukemia Research;2021-01
4. Gilteritinib;Reactions Weekly;2020-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3